Manages vasospastic angina confirmed. Sold as Procardia, Adalat, Procardia Xl, Adalat Cc. Every FDA application for this active ingredient: 4 branded and 32 generic.
As of Nov 16, 2026, FDA lists 36 applications for Nifedipine (sold as Procardia, Adalat, Procardia Xl and others), first approved Dec 31, 1981, with 2 new uses approved and 0 published complete response letters.
| Nifedipine ER | Part D | $91.1M | -8% | 994,791 |
| Procardia XL | Part D | $1.0M | +5% | 357 |
| Nifedipine | Part D | $649K | -9% | 5,399 |
| Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST TrialHypertension in Pregnancy, Obstetrical Complications · The George Washington University Biostatistics Center | Phase 3 | Not yet recruiting | Aug 5, 2026 |
| Oral Nifedipine Versus Placebo for Pain and Healing After HemorrhoidectomyHemorrhoids, Postoperative Pain · Sana'a University | Phase 4 | Not yet recruiting | Jun 22, 2026 |
| Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationSevere High Altitude Pulmonary Edema, Severe High Altitude Cerebral Edema · Tibet Autonomous Region People's Hospital | Not applicable | Not yet recruiting | Jun 10, 2026 |
| Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension StudyHypertension, Postpartum Preeclampsia · The Cleveland Clinic | Not applicable | Recruiting | Jan 23, 2026 |
| Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal DiseaseHemorrhoid Bleeding, Hemorrhoids Prolapse · Cardarelli Hospital | — | Recruiting | Dec 22, 2025 |
| Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort StudyPost-stroke Pneumonia · First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | — | Not yet recruiting | Dec 4, 2025 |
| Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot StudyPostpartum Preeclampsia · Medical College of Wisconsin | Not applicable | Recruiting | Sep 22, 2025 |
| 6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 WeeksChildren Born to Mothers Enrolled in the TOCOPROM Trial · Assistance Publique - Hôpitaux de Paris | — | Recruiting | Aug 28, 2025 |
| Dec 31, 1981 | ProcardiaNDA 18482 · New molecular entity | Pfizer | 42 | Discontinued |
| Nov 27, 1985 | AdalatNDA 19478 · New formulation or manufacturer | Bayer Pharms | 12 | Discontinued |
| Apr 28, 1989 | NifedipineANDA 72556 | Actavis Elizabeth | 22 | Discontinued |
| Apr 28, 1989 | NifedipineANDA 72579 | Actavis Elizabeth | 21 | Marketed |
| Jul 10, 1989 | NifedipineANDA 72409 | Chase Labs Nj | 3 | Discontinued |
| Sep 6, 1989 | Procardia XlNDA 19684 · New dosage form | Pfizer | 22 | Marketed |
| Jun 19, 1991 | NifedipineANDA 73421 | Chase Labs Nj | 2 | Discontinued |
| Oct 8, 1991 | NifedipineANDA 73250 | Velzen Pharma Pvt | 8 | Marketed |
| Feb 19, 1992 | NifedipineANDA 72651 | Teva | 17 | Discontinued |
| Apr 30, 1992 | NifedipineANDA 74045 | Velzen Pharma Pvt | 6 | Marketed |
| Apr 21, 1993 | Adalat CcNDA 20198 · New formulation or manufacturer | Norwich | 16 | Discontinued |
| Jul 30, 1993 | NifedipineANDA 72781 | Acella | 3 | Marketed |
| Dec 17, 1999 | NifedipineANDA 75108 | Pharmobedient | 0 | Discontinued |
| Mar 10, 2000 | Afeditab CrANDA 75128 | Watson Labs Teva | 6 | Discontinued |
| Sep 27, 2000 | NifedipineANDA 75289 | Valeant Pharms North | 6 | Marketed |
| Dec 4, 2000 | NifedipineANDA 75269 | Valeant Pharms North | 6 | Marketed |
| Oct 26, 2001 | Afeditab CrANDA 75659 | Watson Labs | 4 | Discontinued |
| Aug 16, 2002 | NifedipineANDA 76070 | Valeant Pharms North | 1 | Marketed |
| Mar 23, 2004 | NifedipineANDA 75414 | Martec USA LLC | 0 | Marketed |
| Nov 21, 2005 | NifedipineANDA 77127 | Osmotica Pharm US | 2 | Marketed |
| Dec 13, 2006 | NifedipineANDA 77899 | Ph Health | 4 | Discontinued |
| Jun 21, 2010 | NifedipineANDA 90649 | Aurobindo Pharma USA | 6 | Marketed |
| Sep 13, 2010 | NifedipineANDA 90602 | Rising | 0 | Discontinued |
| Dec 3, 2010 | NifedipineANDA 201071 | Rising | 1 | Discontinued |
| Apr 25, 2013 | NifedipineANDA 202644 | Heritage Pharma | 3 | Marketed |
| Apr 3, 2014 | NifedipineANDA 203126 | Twi Pharms | 2 | Marketed |
| Aug 25, 2016 | NifedipineANDA 202987 | Novast Labs | 1 | Marketed |
| Dec 19, 2017 | NifedipineANDA 210012 | Zydus Pharms | 1 | Marketed |
| Jun 29, 2018 | NifedipineANDA 210184 | Zydus Pharms | 0 | Marketed |
| Mar 12, 2019 | NifedipineANDA 210614 | Novast Labs | 0 | Marketed |
| Apr 16, 2019 | NifedipineANDA 210838 | Spil | 0 | Discontinued |
| Nov 18, 2020 | NifedipineANDA 212016 | Elite Pharm Solution | 0 | Marketed |
| Jul 19, 2021 | NifedipineANDA 213361 | Aurobindo Pharma | 0 | Marketed |
| Mar 29, 2022 | NifedipineANDA 216067 | Alkem Labs Ltd | 2 | Marketed |
| Nov 18, 2022 | NifedipineANDA 216019 | Pharmadax | 0 | Discontinued |
| Nov 18, 2022 | NifedipineANDA 216896 | Alembic | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA